Enlarged prostate (BPH): symptoms, treatment, and when to see a GP

What BPH is

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland — the walnut-sized gland that sits below the bladder and surrounds the urethra in men. As the prostate enlarges, it can compress the urethra and irritate the bladder, producing the cluster of urinary symptoms known as lower urinary tract symptoms (LUTS).

BPH is extraordinarily common: roughly half of men aged 50 and around 90% of men in their 80s have histological evidence of BPH, and about a quarter of men over 60 experience bothersome symptoms. The condition is driven by hormonal changes — specifically dihydrotestosterone (DHT) — that stimulate slow, ongoing growth of prostate tissue across the lifespan.

It is important to be clear about what BPH is not. BPH is not prostate cancer and does not turn into prostate cancer; the two conditions arise in different parts of the prostate and follow different biological pathways. Many men have both because both become more common with age.

This article explains how Australian GPs assess BPH symptoms, what treatments are available, and when symptoms warrant urgent attention. Information here is drawn from the Urological Society of Australia and New Zealand (USANZ) guidance, Therapeutic Guidelines (eTG) Genitourinary, and the Australian Medicines Handbook.

Symptoms and what causes them

LUTS are conventionally grouped into three categories:

Storage symptoms relate to how the bladder holds urine — frequency (needing to urinate often), urgency (a sudden compelling need to go), urgency incontinence (leakage with urgency), and nocturia (waking at night to urinate). These can occur because an overactive bladder muscle accompanies BPH in roughly 40% of cases.

Voiding symptoms relate to passing urine — hesitancy (delay in starting the stream), weak or slow stream, intermittency (start-stop flow), straining, and terminal dribble. These are more directly attributable to mechanical obstruction from the enlarged prostate.

Post-micturition symptoms include the sense of incomplete emptying and post-void dribble.

Symptom severity does not closely correlate with prostate size. Some men with very large prostates have minimal symptoms; others with modest enlargement are significantly bothered. Bladder factors — such as detrusor muscle overactivity or weakness — often matter more than gland size.

Several conditions can mimic BPH or coexist with it, including urinary tract infection, prostate cancer, bladder cancer, urethral stricture, neurogenic bladder (for example, from diabetes or spinal disease), polyuria from uncontrolled diabetes or heart failure, and obstructive sleep apnoea (a common cause of nocturia). Medications can also drive symptoms — anticholinergics, opioids, and decongestants can all worsen LUTS.

How GPs assess BPH

Assessment in general practice combines symptom scoring, examination, and basic investigations.

The International Prostate Symptom Score (IPSS) is a validated seven-question survey that quantifies symptom severity and includes a quality-of-life question. A score below 8 generally indicates mild symptoms, 8 to 19 moderate, and 20 or above severe. Tracking IPSS over time helps gauge response to treatment.

Examination typically includes a digital rectal examination (DRE) — to assess prostate size, consistency, and check for nodules — and an abdominal examination to detect a palpable bladder.

Investigations vary by clinical picture but commonly include urinalysis and mid-stream urine (to exclude infection and detect blood), urea and electrolytes (to check kidney function), and a post-void bladder scan (to assess residual urine after urinating).

PSA testing in the context of BPH symptoms warrants a careful conversation. PSA is a blood test that can be elevated in prostate cancer, but it is also raised in BPH, infection, recent ejaculation, and after digital rectal examination. There is genuine debate about the benefits and limitations of PSA screening — false positives lead to biopsies and over-treatment, while genuine cancers can be missed. Australian guidelines support a shared-decision approach, where you and your GP discuss the balance based on your age, family history, ethnicity, and life expectancy. The HealthDirect patient resource provides further information.

Specialist investigations — uroflowmetry, urodynamic studies, ultrasound of the kidneys and bladder, cystoscopy, or MRI of the prostate — are reserved for specific situations such as suspected obstruction, persistent haematuria, suspected cancer, or symptoms not responding to first-line management.

Treatment options

The right treatment depends on symptom severity, prostate size, comorbid conditions, and personal preference. Decisions are made with your GP and, where needed, a urologist.

Lifestyle and behavioural strategies

For mild symptoms — and as a foundation alongside all other treatments — lifestyle adjustments make a real difference. These include reducing fluid intake in the evening, moderating caffeine and alcohol, double voiding, bladder retraining (gradually extending intervals between voids), weight loss, smoking cessation, and treating constipation. Pelvic floor exercises help storage symptoms. The Continence Foundation of Australia provides excellent patient resources on bladder retraining and pelvic floor work.

Alpha-blockers

Alpha-1 blockers per AMH monographs — including tamsulosin, prazosin, alfuzosin, silodosin, and terazosin — relax smooth muscle in the prostate and bladder neck, improving urine flow. They are typically first-line for moderate to severe symptoms because they work within days to weeks.

Common side effects include postural lightheadedness (especially on first dose), retrograde ejaculation (semen entering the bladder rather than expelling forward), and nasal congestion. Importantly, alpha-blockers can cause intraoperative floppy iris syndrome during cataract surgery — always tell your ophthalmologist if you are taking, or have ever taken, an alpha-blocker.

5-alpha-reductase inhibitors

Finasteride and dutasteride block the conversion of testosterone to DHT, shrinking the prostate over about six months. They are typically used when the prostate is enlarged (≥30 g) and reduce the risk of progression and the need for future surgery, as described in eTG Genitourinary.

Two important practical points: these medications halve PSA levels, so values must be doubled when interpreted for cancer screening; and possible side effects include reduced libido and erectile dysfunction in a minority of men.

Combination therapy

For severe symptoms with a large prostate, combining an alpha-blocker with a 5-alpha-reductase inhibitor (such as dutasteride plus tamsulosin in a single tablet) offers superior symptom control compared with either alone, supported by the CombAT trial evidence.

Tadalafil for overlapping erectile dysfunction

Tadalafil 5 mg daily — a PDE5 inhibitor also used for erectile dysfunction — improves BPH symptoms and is particularly useful when both conditions are present. It is available on a PBS Authority basis for this indication (PBS Online).

Medications for overactive bladder symptoms

When storage symptoms (urgency, urgency incontinence) dominate, mirabegron — a beta-3 agonist — or anticholinergic medications (oxybutynin, solifenacin, tolterodine, darifenacin) may be added. Mirabegron is often preferred in older adults because anticholinergics can affect cognition and increase fall risk.

Surgical options

When medications are inadequate or not tolerated, several procedures are available, performed by urologists:

• Transurethral resection of the prostate (TURP) remains the standard procedure for medium-sized prostates.
• Holmium laser enucleation (HoLEP) and similar laser techniques offer comparable or better outcomes, particularly for larger prostates.
• Open, robotic, or laparoscopic prostatectomy is used for very large prostates.
• UroLift and Rezum (water vapour ablation) are minimally invasive procedures that often preserve ejaculation — useful for selected patients prioritising sexual function.
• Prostatic artery embolisation (PAE) is an emerging option in specialist centres.

Your urologist will discuss which procedure suits your prostate size, symptoms, and goals.

When to see your GP

Make an appointment to discuss BPH symptoms when:

• Urinary symptoms are affecting your sleep, work, or quality of life
• You are getting up more than once or twice at night to urinate
• You notice a weakening urinary stream over weeks to months
• You have recurrent urinary tract infections
• You have a family history of prostate cancer and have not had a recent prostate discussion
• You are starting an alpha-blocker and need to know about the cataract-surgery implications
• Current treatment is not working as well as it used to

Routine GP assessment is straightforward, supportive, and gets you on a clear path.

Red flags requiring urgent attention

Seek same-day medical assessment or attend an emergency department for:

Acute urinary retention — a sudden complete inability to pass urine, with growing lower-abdominal pain and a visibly distended bladder. This requires emergency catheterisation.

Visible blood in the urine (macroscopic haematuria) — even a single episode warrants urgent investigation because it can indicate bladder cancer, kidney pathology, or significant urinary tract pathology.

Fever with urinary symptoms — suggests urinary infection or prostatitis that may require urgent antibiotics and assessment for sepsis.

Severe flank pain with urinary symptoms — may indicate pyelonephritis or obstruction.

Significant new symptoms after starting a new medication — particularly retention or marked symptom worsening.

Do not dismiss these signs as part of normal ageing. Australian general practice is well set up to assess them promptly.

What this article is and is not

This is general health information based on current Australian clinical guidance — the USANZ, eTG Genitourinary, the Australian Medicines Handbook, and RACGP resources. It is not personal medical advice and does not create a doctor-patient relationship. Treatment decisions, including which medications are appropriate, whether a PSA test is right for you, and whether to consider surgery, are made collaboratively with your own GP and specialist clinicians.

For Australian patient-friendly information: HealthDirect — Enlarged prostate (BPH) · Better Health Channel · Continence Foundation of Australia.

---

Sources cited

1. Urological Society of Australia and New Zealand (USANZ)
2. Therapeutic Guidelines — eTG Genitourinary
3. Australian Medicines Handbook (AMH)
4. HealthDirect — Enlarged prostate (BPH)
5. Better Health Channel — Prostate
6. Continence Foundation of Australia
7. PBS Online
8. RACGP — Clinical resources